Aptus Pharma Limited's board of directors approved significant corporate restructuring proposals during its meeting held on March 24, 2026. The pharmaceutical company's board sanctioned an authorized share capital enhancement and recommended a 3:2 bonus equity shares issue, with comprehensive regulatory compliance measures in place.

Authorized Share Capital Enhancement

The board approved a substantial increase in the company's authorized share capital structure, subject to shareholder approval. The enhancement represents a strategic expansion to support future growth initiatives and corporate flexibility.

Bonus Equity Shares Recommendation

The board recommended issuing bonus equity shares to existing shareholders in a 3:2 ratio. The bonus shares will be issued by capitalizing ₹10,29,00,000 from the securities premium account, with adequate reserves available for the proposed capitalization.

Share Capital Structure Impact

The bonus issue will significantly transform the company's paid-up share capital structure, with the total number of shares increasing substantially post-implementation.

Postal Ballot and E-Voting Process

The board approved the postal ballot notice along with explanatory statements for both resolutions. Central Depository Services Limited (CDSL) has been appointed as the e-voting agency, with a scrutinizer designated for conducting the process transparently. The company published newspaper advertisements on March 27, 2026, confirming the electronic dispatch of postal ballot notices to eligible shareholders.

Regulatory Compliance and Timeline

The company has obtained statutory auditor certification confirming adequate securities premium reserves of ₹10,67,63,656 as of March 24, 2026. The proposed bonus shares are expected to be credited within two months from board approval, on or before May 23, 2026. Managing Director Tejash Hathi (DIN: 03151221) signed the regulatory communication, with the board meeting conducted from 5:00 PM to 7:15 PM on March 24, 2026. The postal ballot notice has been made available on the company's website and BSE platform for shareholder access.

Aptus Pharma Limited has officially scheduled a board meeting for March 24, 2026, to deliberate on significant corporate actions including the issuance of bonus equity shares and an increase in authorized share capital.

Board Meeting Details

The company has issued a formal notice to BSE Limited under Regulation 29 of SEBI Listing Regulations, confirming that the board meeting will be held at their registered office in Rajkot, Gujarat. The meeting agenda includes two key proposals that require board consideration and subsequent shareholder approval.

Key Agenda Items

The board will consider two significant corporate actions during the meeting. First, the proposal to increase the company's authorized share capital, which will require member approval if recommended by the board. Second, the consideration and recommendation of bonus equity shares, also subject to shareholder approval.

Trading Window Closure

In compliance with SEBI insider trading regulations, the company has announced a trading window closure for all designated persons and their immediate relatives. The trading restriction will be effective from March 18, 2026, through March 26, 2026, covering the period around the board meeting deliberations.

Corporate Action Significance

Bonus shares represent additional equity shares distributed to existing shareholders without requiring additional payment, typically undertaken to reward shareholders and improve market liquidity. The proposed increase in authorized share capital would provide the company with greater flexibility for future capital-raising activities and corporate restructuring initiatives.